published meta-analysis   sensitivity analysis   studies

anti-interleukin-6 in COVID-19 - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62] CORIMUNO-19, 2020 0.92 [0.31; 2.71] COVACTA (Rosas), 2020 1.02 [0.62; 1.68] RCT-TCZ-COVID-19, 2020 2.14 [0.19; 24.21] sarilumab phase 2 high dose, 0 0.78 [0.34; 1.80] sarimulab phase 2 low dose, 0 1.51 [0.69; 3.32] 1.08[0.77; 1.52]BACC Bay Tocilizumab Trial, 2020, CORIMUNO-19, 2020, COVACTA (Rosas), 2020, RCT-TCZ-COVID-19, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 060%1,203seriousnot evaluable clinical improvementdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41] COVACTA (Rosas), 2020 1.19 [0.81; 1.75] EMPACTA, 2020 1.15 [0.90; 1.47] sarilumab phase 2 high dose, 0 2.09 [1.00; 4.36] sarimulab phase 2 low dose, 0 1.51 [0.73; 3.11] 1.17[1.00; 1.38]BACC Bay Tocilizumab Trial, 2020, COVACTA (Rosas), 2020, EMPACTA, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 050%950seriousserious clinical improvement (28-day)detailed resultsCOVACTA (Rosas), 2020 1.19 [0.81; 1.75] 1.19[0.81; 1.75]COVACTA (Rosas), 202010%438moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsEMPACTA, 2020 1.15 [0.90; 1.47] 1.15[0.90; 1.47]EMPACTA, 202010%moderatenot evaluable clinical worseningdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09] CORIMUNO-19, 2020 0.56 [0.26; 1.20] EMPACTA, 2020 0.55 [0.33; 0.92] RCT-TCZ-COVID-19, 2020 1.05 [0.59; 1.86] 0.78[0.53; 1.14]BACC Bay Tocilizumab Trial, 2020, CORIMUNO-19, 2020, EMPACTA, 2020, RCT-TCZ-COVID-19, 2020436%495moderatenot evaluable death or ventilationdetailed resultsBACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81] CORIMUNO-19, 2020 0.56 [0.24; 1.31] EMPACTA, 2020 0.56 [0.32; 0.97] sarilumab phase 2 high dose, 0 0.39 [0.18; 0.82] sarimulab phase 2 low dose, 0 0.70 [0.34; 1.44] 0.59[0.43; 0.80]BACC Bay Tocilizumab Trial, 2020, CORIMUNO-19, 2020, EMPACTA, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 050%643seriousnot evaluable hospital dischargedetailed resultsEMPACTA, 2020 1.16 [0.90; 1.49] 1.16[0.90; 1.49]EMPACTA, 202010%moderatenot evaluable ventilationdetailed resultssarilumab phase 2 high dose, 0 0.27 [0.10; 0.71] sarimulab phase 2 low dose, 0 0.28 [0.11; 0.73] 0.27[0.14; 0.55]sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 020%270seriousnot evaluable off oxygenationdetailed resultssarilumab phase 2 high dose, 0 1.99 [0.95; 4.15] sarimulab phase 2 low dose, 0 1.07 [0.52; 2.21] 1.46[0.79; 2.68]sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0228%270seriousnot evaluable superinfectiondetailed resultsCOVACTA (Rosas), 2020 0.77 [0.48; 1.23] 0.77[0.48; 1.23]COVACTA (Rosas), 202010%438moderatenot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2020-11-25 22:44 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 87,95,94,90,91,97 - treatments: 557,635,553,628,646,645,607,395 - roots T: 290